Defibrillators, Implantable

• 

  Subject Areas on Research

  • 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. 
  • 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. 
  • 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. 
  • 2017 HRS expert consensus statement on magnetic resonance imaging and radiation exposure in patients with cardiovascular implantable electronic devices. 
  • 6-Month Outcomes in Patients With Implantable Cardioverter-Defibrillators Undergoing Renal Sympathetic Denervation for the Treatment of Refractory Ventricular Arrhythmias. 
  • A change of heart. 
  • A clinical trial of ICD programming. 
  • A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. 
  • A covariance-based algorithm: a novel technique for rhythm discrimination in ICDs. 
  • A four-shock Bayesian up-down estimator of the 80% effective defibrillation dose. 
  • A patient with congenital heart disease and ventricular tachycardia: what is the course of the device lead? 
  • A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. 
  • A young patient with exercise-induced polymorphic ventricular tachycardia. 
  • ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). 
  • ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. 
  • ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. 
  • ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. 
  • ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. 
  • ACCF/AHA/AMA-PCPI 2011 performance measures for adults with heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Consortium for Performance Improvement. 
  • ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. 
  • ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. 
  • Age differences in the use of implantable cardioverter-defibrillators among older patients hospitalized with heart failure. 
  • Aldosterone antagonists--last man standing? 
  • Amino acid alterations in fibronectin binding protein A (FnBPA) and bacterial genotype are associated with cardiac device related infection in Staphylococcus aureus bacteraemia. 
  • Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. 
  • Amiodarone versus implantable cardioverter defibrillator for asymptomatic nonsustained ventricular tachycardia in nonischemic dilated cardiomyopathy. 
  • Amplatzer vascular plug closure of a subclavian arteriovenous fistula associated with implantable cardioverter-defibrillator implantation. 
  • An ECG index of myocardial scar enhances prediction of defibrillator shocks: an analysis of the Sudden Cardiac Death in Heart Failure Trial. 
  • Analysis of Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice. 
  • Analysis of ventricular activation using surface electrocardiography to predict left ventricular reverse volumetric remodeling during cardiac resynchronization therapy. 
  • Antitachycardia pacing for termination of ventricular tachyarrhythmias: should we use it? 
  • Applying the new STEMI guidelines: 2. Disturbances of cardiac rhythm after ST-segment elevation myocardial infarction. 
  • Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? 
  • Are racial/ethnic gaps in the use of cardiac resynchronization therapy narrowing?: an analysis of 107,096 patients from the National Cardiovascular Data Registry's ICD Registry. 
  • Arrhythmogenic right ventricular dysplasia: a United States experience. 
  • Assessing the appropriateness of ICD use "appropriately". 
  • Assessment of myocardial scarring improves risk stratification in patients evaluated for cardiac defibrillator implantation. 
  • Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention. 
  • Association between frequency of atrial and ventricular ectopic beats and biventricular pacing percentage and outcomes in patients with cardiac resynchronization therapy. 
  • Association between left ventricular ejection fraction post-cardiac resynchronization treatment and subsequent implantable cardioverter defibrillator therapy for sustained ventricular tachyarrhythmias. 
  • Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT. 
  • Association between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35%. 
  • Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes: A Multicenter Registry Study. 
  • Association of prolonged QRS duration with ventricular tachyarrhythmias and sudden cardiac death in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). 
  • Atrial fibrillation and stroke: it's not necessarily all about the rhythm. 
  • Audible implantable cardioverter defibrillator alarms detect intermittent conductor discontinuity. 
  • Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. 
  • Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial. 
  • Baseline fragmented QRS is associated with increased all-cause mortality in heart failure with reduced ejection fraction: A systematic review and meta-analysis. 
  • Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology. 
  • Bronchopericardial fistula after placement of an automatic implantable cardioverter defibrillator: radiographic and CT findings. 
  • CIED malfunction in patients receiving radiation is a rare event that could be detected by remote monitoring. 
  • Cable externalization and electrical failure of the Riata family of implantable cardioverter-defibrillator leads: A systematic review and meta-analysis. 
  • Cardiac MRI scar patterns differ by sex in an implantable cardioverter-defibrillator and cardiac resynchronization therapy cohort. 
  • Cardiac Magnetic Resonance Scar Imaging for Sudden Cardiac Death Risk Stratification in Patients with Non-Ischemic Cardiomyopathy. 
  • Cardiac implantable electronic device lead extraction in patients with underlying infection using open thoracotomy or percutaneous techniques. 
  • Cardiac implantable electronic device removal in patients with left ventricular assist device associated infections. 
  • Cardiac resynchronization therapy in heart failure patients: an update. 
  • Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial. 
  • Cardiac-resynchronization therapy for the prevention of heart-failure events. 
  • Care disparities: moving from gray to black and white. 
  • Case 12-2-1998. Noncardiac surgery and pacemaker cardioverter-defibrillator management. 
  • Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial. 
  • Causes and consequences of discontinuation of the implantable cardioverter-defibrillator therapy in non-terminally ill patients. 
  • Centers for Medicare and Medicaid Services' Decision to Reconsider Coverage Indications for ICDs: Where to Now? 
  • Change in intrathoracic impedance measures during acute decompensated heart failure admission: results from the Diagnostic Data for Discharge in Heart Failure Patients (3D-HF) Pilot Study. 
  • Characterization and predictors of first and subsequent inappropriate ICD therapy by heart rate ranges: Result of the MADIT-RIT efficacy analysis. 
  • Chest pain associated with moderator band pacing. 
  • Choosing the optimal monophasic and biphasic waveforms for ventricular defibrillation. 
  • Cigarette smoking and the risk of supraventricular and ventricular tachyarrhythmias in high-risk cardiac patients with implantable cardioverter defibrillators. 
  • Circumstances and outcomes of sudden unexpected death in patients with high-risk myocardial infarction: implications for prevention. 
  • Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members. 
  • Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. 
  • Clinical cardiac electrophysiology fellowship teaching objectives for the new millennium. 
  • Clinical characteristics and outcome of infective endocarditis involving implantable cardiac devices. 
  • Clinical effectiveness of CRT and ICD therapy in heart failure patients by racial/ethnic classification: insights from the IMPROVE HF registry. 
  • Clinical effectiveness of cardiac resynchronization and implantable cardioverter-defibrillator therapy in men and women with heart failure: findings from IMPROVE HF. 
  • Clinical effectiveness of cardiac resynchronization therapy versus medical therapy alone among patients with heart failure: analysis of the ICD Registry and ADHERE. 
  • Clinical effectiveness of implantable cardioverter-defibrillators among medicare beneficiaries with heart failure. 
  • Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. 
  • Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure) study. 
  • Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease. 
  • Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry. 
  • Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women. 
  • Comparative effectiveness of cardiac resynchronization therapy with an implantable cardioverter-defibrillator versus defibrillator therapy alone: a cohort study. 
  • Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF. 
  • Complexities of defibrillator deactivation. 
  • Complications from prophylactic replacement of cardiac implantable electronic device generators in response to United States Food and Drug Administration recall: A systematic review and meta-analysis. 
  • Congenital long QT syndrome: considerations for primary care physicians. 
  • Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age. 
  • Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. 
  • Cost-effectiveness of implantable cardioverter-defibrillators. 
  • Cost-effectiveness of the implantable cardioverter defibrillator. 
  • Cross communication. Avoiding device interference in pacemakers and ICDs. 
  • Decision-Making of Patients With Implantable Cardioverter-Defibrillators at End of Life: Family Members' Experiences. 
  • Defibrillation causes immediate cardiac dilation in humans. 
  • Defibrillators: Selecting the Right Device for the Right Patient. 
  • Design and rationale of the ANALYZE ST study: a prospective, nonrandomized, multicenter ST monitoring study to detect acute coronary syndrome events in implantable cardioverter-defibrillator patients. 
  • Design of the SHock Inhibition Evaluation with Azimilide (SHIELD) study: a novel method to assess antiarrhythmic drug effect in patients with an implantable cardioverter-defibrillator. 
  • Designation and distribution of events in the Multicenter UnSustained Tachycardia Trial (MUSTT). 
  • Developing a risk model for in-hospital adverse events following implantable cardioverter-defibrillator implantation: a report from the NCDR (National Cardiovascular Data Registry). 
  • Device therapy in heart failure patients with chronic kidney disease. 
  • Device therapy in the management of congestive heart failure. 
  • Diagnostic Accuracy of 18F-FDG PET/CT in Infective Endocarditis and Implantable Cardiac Electronic Device Infection: A Cross-Sectional Study. 
  • Disparity Between Indications for and Utilization of Implantable Cardioverter Defibrillators in Asian Patients With Heart Failure. 
  • Dissociation rate constants of human fibronectin binding to fibronectin-binding proteins on living Staphylococcus aureus isolated from clinical patients. 
  • Distributed decision support using a web-based interface: prevention of sudden cardiac death. 
  • Do ICD lead recalls affect physician--or patient--behavior? If not, why not? 
  • Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator? 
  • Do physicians' attitudes toward implantable cardioverter defibrillator therapy vary by patient age, gender, or race? 
  • Does Age Influence Cardiac Resynchronization Therapy Use and Outcome? 
  • Does ICD therapy benefit women with a history of myocardial infarction and severe left ventricular dysfunction? 
  • Does reducing capacitance have potential for further miniaturisation of implantable defibrillators? 
  • Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients? 
  • ECG myocardial scar quantification predicts reverse left ventricular remodeling and survival after cardiac resynchronization therapy implantation: A retrospective pilot study. 
  • ECG quantification of myocardial scar and risk stratification in MADIT-II. 
  • ECG quantification of myocardial scar in cardiomyopathy patients with or without conduction defects: correlation with cardiac magnetic resonance and arrhythmogenesis. 
  • Early echocardiographic deformation analysis for the prediction of sudden cardiac death and life-threatening arrhythmias after myocardial infarction. 
  • Early failure of a small diameter high-voltage implantable cardioverter-defibrillator lead. 
  • Early repolarization associated with ventricular arrhythmias in patients with chronic coronary artery disease. 
  • Easy to Predict, Difficult to Prevent. 
  • Editorial associated with article: 'Optimal response to cardiac arrest study' by Dr. P. Martens. 
  • Educational and psychological interventions to improve outcomes for recipients of implantable cardioverter defibrillators and their families: a scientific statement from the American Heart Association. 
  • Educational videos to reduce racial disparities in ICD therapy via innovative designs (VIVID): a randomized clinical trial. 
  • Effect of beta-blocking therapy on outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT). 
  • Effect of cardiac resynchronization therapy and implantable cardioverter defibrillator on quality of life in patients with heart failure: a meta-analysis. 
  • Effect of defibrillation threshold testing on heart failure hospitalization or death in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). 
  • Effect of implantable defibrillators on arrhythmic events and mortality in the multicenter unsustained tachycardia trial. 
  • Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. 
  • Effective defibrillation in pigs using interleaved and common phase sequential biphasic shocks. 
  • Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). 
  • Effectiveness of high rate and delayed detection ICD programming by race: A MADIT-RIT substudy. 
  • Effectiveness of implantable cardioverter-defibrillators in survivors of inhospital cardiac arrest. 
  • Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). 
  • Effects of implantable cardioverter/defibrillator shock and antitachycardia pacing on anxiety and quality of life: A MADIT-RIT substudy. 
  • Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial. 
  • Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. 
  • Ejection fraction assessment and survival: an analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial. 
  • Electromechanical associations. 
  • Electrophysiologic and clinical effects of angiotensin-converting enzyme inhibitors in patients with prior myocardial infarction, nonsustained ventricular tachycardia, and depressed left ventricular function. MUSTT Investigators. Multicenter UnSustained Tachycardia Trial. 
  • Electrophysiologic testing to identify patients at risk for sudden death. 
  • End-of-life care in patients with implantable cardioverter defibrillators: a MADIT-II substudy. 
  • Epidemiology, management, and outcomes of sustained ventricular arrhythmias after continuous-flow left ventricular assist device implantation. 
  • Evaluation of diagnostic imaging technologies and therapeutics devices: better information for better decisions: proceedings of a multidisciplinary workshop. 
  • Evaluation of outpatients experiencing implantable cardioverter defibrillator shocks associated with minimal symptoms. 
  • Evidence of clinical practice heterogeneity in the use of implantable cardioverter-defibrillators in heart failure and post-myocardial infarction left ventricular dysfunction: Findings from IMPROVE HF. 
  • Evidence-based medicine and policy: the case of the implantable cardioverter defibrillator. 
  • Exercise training and implantable cardioverter-defibrillator shocks in patients with heart failure: results from HF-ACTION (Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing). 
  • Expanding the benefits of implantable cardioverter-defibrillator therapy: "is less more"? 
  • Extent of and reasons for nonuse of implantable cardioverter defibrillator devices in clinical practice among eligible patients with left ventricular systolic dysfunction. 
  • Extraction of defibrillator leads recalled for cable externalization and failure. 
  • Factors associated with improvement in guideline-based use of ICDs in eligible heart failure patients. 
  • Factors associated with ventricular inducibility in the MADIT-II study population. 
  • Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). 
  • Failure to reassess ejection fraction after acute myocardial infarction in potential implantable cardioverter/defibrillator candidates: insights from the Translational Research Investigating Underlying disparities in acute Myocardial infarction Patients' Health Status (TRIUMPH) registry. 
  • Failure-free survival of the Durata defibrillator lead. 
  • Feedback to providers improves evidence-based implantable cardioverter-defibrillator programming and reduces shocks. 
  • Fidelis Replacement: Can We Abandon With Reckless Abandon? 
  • Follow-up of patients with new cardiovascular implantable electronic devices: are experts' recommendations implemented in routine clinical practice? 
  • Follow-up of patients with new cardiovascular implantable electronic devices: is adherence to the experts' recommendations associated with improved outcomes? 
  • Fractal correlation properties of heart rate dynamics and adverse events in patients with implantable cardioverter-defibrillators. 
  • Frequency of Contact Allergy to Implanted Cardiac Devices. 
  • Future Research Prioritization: Implantable Cardioverter-Defibrillator Therapy in Older Patients. 
  • Heart failure severity, inappropriate ICD therapy, and novel ICD programming: a MADIT-RIT substudy. 
  • Hemiazygous coil placement for high-defibrillation thresholds in a patient with a right-sided implantable cardioverter defibrillator. 
  • Highlights of Heart Rhythm 2004, the Annual Scientific Sessions of the Heart Rhythm Society: May 19 to 22, 2004, in San Francisco, California. 
  • Highlights of Heart Rhythm 2005, the Annual Scientific Sessions of the Heart Rhythm Society, May 4-7, 2005, New Orleans, Louisiana. 
  • Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry. 
  • Hypertrophic cardiomyopathy: etiology, diagnosis, and treatment. 
  • INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) Profiling Identifies Ambulatory Patients at High Risk on Medical Therapy After Hospitalizations for Heart Failure. 
  • Images in clinical medicine. Internal ventricular defibrillation. 
  • Impact of baseline heart failure burden on post-implantable cardioverter-defibrillator mortality among medicare beneficiaries. 
  • Impact of immortal person-time and time scale in comparative effectiveness research for medical devices: a case for implantable cardioverter-defibrillators. 
  • Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. 
  • Impact of remote monitoring on clinical events and associated health care utilization: A nationwide assessment. 
  • Implant healing in experimental animal models of diabetes. 
  • Implantable Cardiac Alert System for Early Recognition of ST-Segment Elevation Myocardial Infarction. 
  • Implantable Cardioverter Defibrillators for Nonischemic Cardiomyopathy-Reply. 
  • Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction. 
  • Implantable Cardioverter-Defibrillators Have Stood the Test of Time! 
  • Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy: A Systematic Review and Meta-analysis. 
  • Implantable Cardioverter-Defibrillators in Patients With Left Ventricular Assist Devices: On Trial and in Need of a Trial. 
  • Implantable Defibrillators for Primary Prevention of Sudden Death in Patients on Dialysis. 
  • Implantable cardioverter defibrillator in high-risk long QT syndrome patients. 
  • Implantable cardioverter defibrillator therapy in patients with prior coronary revascularization in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. 
  • Implantable cardioverter defibrillators in Israel: utilization and implantation trends. 
  • Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. 
  • Implantable cardioverter defibrillators: risks accompany the life-saving benefits. 
  • Implantable cardioverter-defibrillator implantation in a patient with atrial standstill. 
  • Implantable cardioverter-defibrillator implementation in acute heart failure syndromes: unanswered questions. 
  • Implantable cardioverter-defibrillator therapy and risk of congestive heart failure or death in MADIT II patients with atrial fibrillation. 
  • Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. 
  • Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials. 
  • Implantable cardioverter-defibrillators for primary prevention: how do the data pertain to the aged? 
  • Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes. 
  • Implantable cardioverter-defibrillators in patients hospitalized for heart failure with chronically reduced left ventricular ejection fraction. 
  • Implantable cardioverter-defibrillators. 
  • Implantable intravascular defibrillator: evaluation of defibrillation waveforms with inferior vena cava electrode system. 
  • Improved patient selection for implantable defibrillators. 
  • Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy. 
  • Improved survival in patients enrolled promptly into remote monitoring following cardiac implantable electronic device implantation. 
  • Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. 
  • Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates. 
  • In heart failure, automatic implant-based telemonitoring reduced a composite of cardiac events and mortality. 
  • In response. 
  • Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. 
  • Incidence and predictors of appropriate therapies delivered by the implantable cardioverter defibrillator in patients with ischemic cardiomyopathy: a systematic review. 
  • Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. 
  • Increased Nonalternans Repolarization Variability Precedes Ventricular Tachycardia Onset in Patients with Implantable Defibrillators. 
  • Increasing rates of cardiac device infections among Medicare beneficiaries: 1990-1999. 
  • Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. 
  • Influence of epicardial patches on defibrillation threshold with nonthoracotomy lead configurations. 
  • Influence of gender on arrhythmia characteristics and outcome in the Multicenter UnSustained Tachycardia Trial. 
  • Influence of healthy candidate bias in assessing clinical effectiveness for implantable cardioverter-defibrillators: cohort study of older patients with heart failure. 
  • Initial United States experience with the Paracor HeartNet myocardial constraint device for heart failure. 
  • Interactions between transvenous nonthoracotomy cardioverter defibrillator systems and permanent transvenous endocardial pacemakers. 
  • Internal cardioversion in two patients with atrial fibrillation refractory to external cardioversion. 
  • International Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in children. 
  • Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes? 
  • Is biology destiny or can we optimize care for all patients? 
  • Is heart failure guideline adherence being underestimated? The impact of therapeutic contraindications. 
  • Isolated Noncompaction of the Left Ventricle in Adults. 
  • Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. 
  • Laser-assisted extraction of pacemaker and defibrillator leads: the role of the cardiac surgeon. 
  • Left bundle branch block predicts better survival in women than men receiving cardiac resynchronization therapy: long-term follow-up of ∼ 145,000 patients. 
  • Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. 
  • Letter by Bourque et al regarding article, "Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994". 
  • Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. 
  • Localization of pacing and defibrillator leads using standard x-ray views is frequently inaccurate and is not reproducible. 
  • Long-Term Post-Discharge Risks in Older Survivors of Myocardial Infarction With and Without Out-of-Hospital Cardiac Arrest. 
  • Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. 
  • Longitudinal follow-up of implantable cardioverter defibrillator leads. 
  • MADIT-II: clinical implications. 
  • MY APPROACH to the risk stratification of patients for sudden cardiac death. 
  • Management Considerations in Infective Endocarditis: A Review. 
  • Management of Ventricular Arrhythmias and Sudden Cardiac Death Risk Associated With Cardiac Channelopathies. 
  • Management of acute decompensated heart failure. 
  • Management of pace-terminated ventricular arrhythmias. 
  • Management of recalled pacemakers and implantable cardioverter-defibrillators: a decision analysis model. 
  • Mandatory diagnostic screening tests to individualize therapy: a curious paradox. 
  • Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. 
  • Mechanical dyssynchrony evaluated by tissue Doppler cross-correlation analysis is associated with long-term survival in patients after cardiac resynchronization therapy. 
  • Mechanisms of inappropriate defibrillator therapy in a modern cohort of remotely monitored patients. 
  • Mechanisms of ventricular fibrillation initiation in MADIT II patients with implantable cardioverter defibrillators. 
  • Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients. 
  • More bad news for cardiac resynchronization therapy in atrial fibrillation patients: what to do? 
  • Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). 
  • Multicenter Automatic Defibrillator Implantation Trial-Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol. 
  • Multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT): design and clinical protocol. 
  • Multicenter automatic defibrillator implantation trial: reduce inappropriate therapy (MADIT-RIT): background, rationale, and clinical protocol. 
  • Multiple Comorbidities and Response to Cardiac Resynchronization Therapy: MADIT-CRT Long-Term Follow-Up. 
  • Neural modulation for hypertension and heart failure. 
  • New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials. 
  • No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • No benefit of a dual coil over a single coil ICD lead: evidence from the Sudden Cardiac Death in Heart Failure Trial. 
  • Non-evidence-based ICD implantations in the United States. 
  • Novel ICD Programming and Inappropriate ICD Therapy in CRT-D Versus ICD Patients: A MADIT-RIT Sub-Study. 
  • Novel approaches to clinical trials: device-related infections. 
  • Novel intravascular defibrillator: defibrillation thresholds of intravascular cardioverter-defibrillator compared to conventional implantable cardioverter-defibrillator in a canine model. 
  • Novel mechanism of premature battery failure due to lithium cluster formation in implantable cardioverter-defibrillators. 
  • Operational use and patient monitoring in a multiplace hyperbaric chamber. 
  • Optimal defibrillator patch configurations include the right side of the heart and left ventricle. 
  • Optimal management of Riata leads with no known electrical abnormalities or externalization: a decision analysis. 
  • Optimal medical therapy use among patients receiving implantable cardioverter/defibrillators: insights from the National Cardiovascular Data Registry. 
  • Optimal timing of implantable cardioverter-defibrillator implantation after myocardial infarction: a decision analysis. 
  • Optimal utilization and management of implanted cardiac rhythm devices in patients hospitalized for heart failure. 
  • Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. 
  • Outcomes 1 Year After Implantable Cardioverter-Defibrillator Lead Abandonment Versus Explantation for Unused or Malfunctioning Leads: A Report from the National Cardiovascular Data Registry. 
  • Outcomes Among Older Patients Receiving Implantable Cardioverter-Defibrillators for Secondary Prevention: From the NCDR ICD Registry. 
  • Outcomes Associated With Extraction Versus Capping and Abandoning Pacing and Defibrillator Leads. 
  • Outcomes Associated With Subcutaneous Implantable Cardioverter Defibrillators-Reply. 
  • Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims. 
  • Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials. 
  • PR interval identifies clinical response in patients with non-left bundle branch block: a Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy substudy. 
  • Part II: Sealing holes in the safety net. 
  • Patient and implanting physician factors associated with mortality and complications after implantable cardioverter-defibrillator implantation, 2002-2005. 
  • Patient preference in the decision to place implantable cardioverter-defibrillators. 
  • Patient, physician, and procedural factors influencing the use of defibrillation testing during initial implantable cardioverter defibrillator insertion: findings from the NCDR®. 
  • Percutaneous intravascular defibrillator: preliminary data and many questions. 
  • Perioperative cardiac arrhythmias. 
  • Perioperative management of cardiovascular implantable electronic devices: what every anesthesiologist needs to know. 
  • Permanently implantable diagnostic computerized devices: where is the regulatory rar? 
  • Physicians' knowledge and attitudes regarding implantable cardioverter-defibrillators. 
  • Physicians' preferences and attitudes about end-of-life care in patients with an implantable cardioverter-defibrillator. 
  • Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. 
  • Postimplantation ventricular ectopic burden and clinical outcomes in cardiac resynchronization therapy-defibrillator patients: a MADIT-CRT substudy. 
  • Postmarket surveillance and returned product analysis: success but not transparency. 
  • Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. 
  • Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation. 
  • Predicting appropriate shocks in patients with heart failure: Patient level meta-analysis from SCD-HeFT and MADIT II. 
  • Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. 
  • Predictors of an inadequate defibrillation safety margin at ICD implantation: insights from the National Cardiovascular Data Registry. 
  • Predictors of appropriate implantable defibrillator therapies in patients with arrhythmogenic right ventricular dysplasia. 
  • Predictors of mortality in patients with chronic kidney disease and an implantable defibrillator: an EPGEN substudy. 
  • Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. 
  • Prescription of Guideline-Recommended Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Among Patients Hospitalized With Heart Failure and Varying Degrees of Renal Function. 
  • Preventing tomorrow's sudden cardiac death today: dissemination of effective therapies for sudden cardiac death prevention. 
  • Preventing tomorrow's sudden cardiac death today: part II: Translating sudden cardiac death risk assessment strategies into practice and policy. 
  • Prevention of sudden death in patients with coronary artery disease. 
  • Prevention of sudden death in patients with coronary artery disease: the Multicenter Unsustained Tachycardia Trial (MUSTT). 
  • Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: A Meta-analysis. 
  • Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: Diminishing Returns With Advancing Age? 
  • Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Cardiomyopathy. 
  • Primary prevention implantable cardioverter defibrillators are effective in preventing overall mortality in older patients. 
  • Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study. 
  • Primary prevention implantable cardioverter defibrillators in women: More questions than answers. 
  • Primary prevention implantable cardioverter-defibrillators and survival in older women. 
  • Primary prevention implantable cardioverter-defibrillators in older racial and ethnic minority patients. 
  • Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial. 
  • Prognostic importance of defibrillator shocks in patients with heart failure. 
  • Promoting Transparency in Trials: Lessons From the COMPANION Investigators. 
  • Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. 
  • Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. 
  • Prophylactic implantable defibrillator patches in patients at high risk for malignant ventricular dysrhythmias. 
  • Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. 
  • Proportion of patients followed in a specialized heart failure clinic needing an implantable cardioverter defibrillator as determined by applying different trial eligibility criteria. 
  • Quality improvement in heart rhythm care: the path forward. 
  • Quality of care and outcomes in women hospitalized for heart failure. 
  • Quality of life in patients with implantable cardioverter-defibrillator: systematic review of randomized controlled trials. 
  • Quality of life in pediatric patients with implantable cardioverter defibrillators. 
  • Quality of life with defibrillator therapy or amiodarone in heart failure. 
  • Racial differences in outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT): a comparison of whites versus blacks. 
  • Racial disparity in the utilization of implantable-cardioverter defibrillators among patients with prior myocardial infarction and an ejection fraction of  
  • Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial. 
  • Rapid-rate nonsustained ventricular tachycardia found on implantable cardioverter-defibrillator interrogation: relationship to outcomes in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • Rates of and factors associated with infection in 200 909 Medicare implantable cardioverter-defibrillator implants: results from the National Cardiovascular Data Registry. 
  • Rationale and design for the Defibrillators to Reduce Risk by Magnetic Resonance Imaging Evaluation (DETERMINE) trial. 
  • Rationale, design, and baseline characteristics of a Program to Assess and Review Trending INformation and Evaluate CorRelation to Symptoms in Patients with Heart Failure (PARTNERS HF). 
  • Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients with heart failure. 
  • Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction. 
  • Reduction in Inappropriate ICD Therapy in MADIT-RIT Patients Without History of Atrial Tachyarrhythmia. 
  • Reduction in inappropriate therapy and mortality through ICD programming. 
  • Regional variations in physicians' attitudes and recommendations surrounding implantable cardioverter-defibrillators. 
  • Relation between renal function and response to cardiac resynchronization therapy in Multicenter Automatic Defibrillator Implantation Trial--Cardiac Resynchronization Therapy (MADIT-CRT). 
  • Relation between time from myocardial infarction to enrolment and patient outcomes in the Multicenter UnSustained Tachycardia Trial. 
  • Relation of 12-lead electrocardiogram patterns to implanted defibrillator-terminated ventricular tachyarrhythmias in hypertrophic cardiomyopathy. 
  • Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: an analysis of patients enrolled in the multicenter unsustained tachycardia trial. 
  • Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION. 
  • Remote monitoring of cardiac implantable electronic devices (CIED). 
  • Remote monitoring of implantable cardioverter defibrillators versus quarterly device interrogations in clinic: results from a randomized pilot clinical trial. 
  • Renal sympathetic denervation and ventricular arrhythmias: a case of electrical storm with multiple renal arteries. 
  • Reply: The Benefit of Cardiac Resynchronization Therapy Is Not Hindered by the Number of Comorbidities. 
  • Reply: rapid rate nonsustained ventricular tachycardia found on ICD interrogation: relationship of RR-NSVT to outcomes in the SCD-HeFT trial. 
  • Representation of black patients in randomized clinical trials of heart failure with reduced ejection fraction. 
  • Response by Friedman and Al-Khatib to Letter Regarding Article, "Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: Report From the National Cardiovascular Data Registry". 
  • Response by Hess et al to Letter Regarding Article, "Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Program". 
  • Response to Letter Regarding Article, "Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women". 
  • Response to letter regarding article, "Rates of and factors associated with infection in 200 909 Medicare implantable cardioverter-defibrillator implants: results from the National Cardiovascular Data Registry". 
  • Response to letter regarding, "PR interval identifies clinical response in patients with non-left bundle branch block: a multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy sub-study" by Kutyifa et al. 
  • Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT. 
  • Results of the multicenter RENEWAL 3 AVT clinical study of cardiac resynchronization defibrillator therapy in patients with paroxysmal atrial fibrillation. 
  • Rethinking papillary muscle resection for refractory ventricular tachycardia in the LVAD era. A case report. 
  • Return on Investment in Implantable Devices: Cardiac Resynchronization Therapy in Mildly Symptomatic Heart Failure. 
  • Review of advanced heart failure device diagnostics examined in clinical trials and the potential benefit from monitoring capabilities. 
  • Review of the registry's fourth year, incorporating lead data and pediatric ICD procedures, and use as a national performance measure. 
  • Right ventricular dysfunction and the incidence of implantable cardioverter-defibrillator therapies. 
  • Right, but not left, bundle branch block is associated with large anteroseptal scar. 
  • Risk factors for recurrent heart failure events in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). 
  • Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Risk stratification in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. 
  • Risk stratification of individuals with the Brugada electrocardiogram: a myth or a reality? 
  • Risks and challenges of implantable cardioverter-defibrillators in young adults. 
  • Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure. 
  • Role of implantable cardioverter defibrillator therapy in patients with long QT syndrome. 
  • Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy. 
  • SCD-HeFT: Use of R-R interval statistics for long-term risk stratification for arrhythmic sudden cardiac death. 
  • SPECT myocardial perfusion imaging for the assessment of left ventricular mechanical dyssynchrony. 
  • Safety and Efficacy of Exercise Training in Patients With an Implantable Cardioverter-Defibrillator: A Meta-Analysis. 
  • Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. 
  • Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. 
  • Safety of serial MRI in patients with implantable cardioverter defibrillators. 
  • Same-day discharge and risks of mortality and readmission after elective ICD placement for primary prevention. 
  • Sensing lead insulation fractures following implantable cardioverter-defibrillator placement. 
  • Session highlights from the American Heart Association Scientific Sessions: November 9-12, 1997. 
  • Sex Differences in Inappropriate ICD Device Therapies: MADIT-II and MADIT-CRT. 
  • Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings from the Get With The Guidelines-Heart Failure Program. 
  • Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. 
  • Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. 
  • Simplified peak power reserve in patients with an implantable cardioverter-defibrillator and advanced heart failure. 
  • Single vs. dual chamber implantable cardioverter-defibrillators or programming of implantable cardioverter-defibrillators in patients without a bradycardia pacing indication: systematic review and meta-analysis. 
  • Spinal cord stimulation for intercostal neuralgia in a patient with implantable cardiac defibrillator and biventricular pacing. 
  • Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators. 
  • Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Subclinical and Device-Detected Atrial Fibrillation: Pondering the Knowledge Gap: A Scientific Statement From the American Heart Association. 
  • Sudden Cardiac Death Among Hemodialysis Patients. 
  • Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). 
  • Sudden cardiac arrest in ESRD patients. 
  • Sudden cardiac death in hemodialysis patients: a comprehensive care approach to reduce risk. 
  • Surgical therapy for sudden cardiac death in children. 
  • Surgical treatment of pacemaker and defibrillator lead endocarditis: the impact of electrode lead extraction on outcome. 
  • Survival After Secondary Prevention Implantable Cardioverter-Defibrillator Placement: An Analysis From the NCDR ICD Registry. 
  • Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease. 
  • Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials. 
  • Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials. 
  • Survival in Women Versus Men Following Implantation of Pacemakers, Defibrillators, and Cardiac Resynchronization Therapy Devices in a Large, Nationwide Cohort. 
  • Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. 
  • Survival with cardiac-resynchronization therapy in mild heart failure. 
  • Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study. 
  • Temporal Trends in and Factors Associated With Use of Single- Versus Dual-Coil Implantable Cardioverter-Defibrillator Leads: Data From the NCDR ICD Registry. 
  • Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure: Analysis From the American Heart Association Get With The Guidelines-Heart Failure Registry. 
  • Temporal complexity of repolarization and mortality in patients with implantable cardioverter defibrillators. 
  • The 2004 ACC/AHA Guidelines: a perspective and adaptation for Canada by the Canadian Cardiovascular Society Working Group. 
  • The ABCs of managing systolic heart failure: Past, present, and future. 
  • The Heart Rhythm Society (HRS)/American Society of Anesthesiologists (ASA) Expert Consensus Statement on the perioperative management of patients with implantable defibrillators, pacemakers and arrhythmia monitors: facilities and patient management this document was developed as a joint project with the American Society of Anesthesiologists (ASA), and in collaboration with the American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). 
  • The Heart Rhythm Society (HRS)/American Society of Anesthesiologists (ASA) Expert Consensus Statement on the perioperative management of patients with implantable defibrillators, pacemakers and arrhythmia monitors: facilities and patient management: executive summary this document was developed as a joint project with the American Society of Anesthesiologists (ASA), and in collaboration with the American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). 
  • The National Cardiovascular Data Registry Voluntary Public Reporting Program: An Interim Report From the NCDR Public Reporting Advisory Group. 
  • The National ICD Registry Report: version 2.1 including leads and pediatrics for years 2010 and 2011. 
  • The Relationship Between Level of Adherence to Automatic Wireless Remote Monitoring and Survival in Pacemaker and Defibrillator Patients. 
  • The S1103Y cardiac sodium channel variant is associated with implantable cardioverter-defibrillator events in blacks with heart failure and reduced ejection fraction. 
  • The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling. 
  • The clinical implications of cumulative right ventricular pacing in the multicenter automatic defibrillator trial II. 
  • The detection and treatment of subclinical atrial fibrillation: evaluating the IMPACT of a comprehensive strategy based on remote arrhythmia monitoring. 
  • The effect of inducing ventricular fibrillation with 50-Hz pacing versus T wave stimulation on the ability to defibrillate. 
  • The effect of intermittent atrial tachyarrhythmia on heart failure or death in cardiac resynchronization therapy with defibrillator versus implantable cardioverter-defibrillator patients: a MADIT-CRT substudy (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). 
  • The efficacy and safety of cardiac resynchronization therapy combined with implantable cardioverter defibrillator for heart failure: a meta-analysis of 5674 patients. 
  • The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. 
  • The high cost of implantable defibrillators. 
  • The interplay between CKD, sudden cardiac death, and ventricular arrhythmias. 
  • The probability of defibrillation success and the incidence of postshock arrhythmia as a function of shock strength. 
  • The relation between patients' outcomes and the volume of cardioverter-defibrillator implantation procedures performed by physicians treating Medicare beneficiaries. 
  • The relationship between baseline and follow-up left ventricular ejection fraction with adverse events among primary prevention ICD patients. 
  • The subcutaneous implantable cardioverter-defibrillator in review. 
  • The use of implantable cardioverter defibrillators for the prevention of sudden cardiac death: a review of the evidence and implications. 
  • Thyroid function in heart failure and impact on mortality. 
  • Time dependence of arrhythmias in ICD patients. 
  • Time-dependent risk of Fidelis lead failure. 
  • Time-dependent risk reduction of ventricular tachyarrhythmias in cardiac resynchronization therapy patients: a MADIT-RIT sub-study. 
  • Toward a more materialistic medicine: the value of authentic materialism within current and future medical practice. 
  • Toward more optimal use of primary prevention implantable cardioverter-defibrillators: how do we get there? 
  • Transient data stream dissociation in computerized data acquisition system masquerading as a sensing abnormality. 
  • Trends and In-Hospital Outcomes Associated With Adoption of the Subcutaneous Implantable Cardioverter Defibrillator in the United States. 
  • Trends in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries. 
  • Trends in use of implantable cardioverter-defibrillator therapy among patients hospitalized for heart failure: have the previously observed sex and racial disparities changed over time? 
  • Unexpected deviation in circadian variation of ventricular arrhythmias: the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • Update on implantable cardioverter defibrillator trials. 
  • Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia. 
  • Use of Implantable Cardioverter-Defibrillators Among Medicare Patients--Reply. 
  • Use of Preprocedural MDCT for Cardiac Implantable Electric Device Lead Extraction: Frequency of Findings That Change Management. 
  • Use of beta-blockers in patients with an implantable cardioverter defibrillator. 
  • Use of cardiac implantable electronic devices in older adults with cognitive impairment. 
  • Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation. 
  • Use of implantable cardioverter defibrillator and anti-arrhythmic agents in a parturient. 
  • Use of implantable cardioverter-defibrillators for primary prevention in older patients: a systematic literature review and meta-analysis. 
  • Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • Utility of implantable cardioverter defibrillators in chronic kidney disease. 
  • Venous thrombosis and stenosis after implantation of pacemakers and defibrillators. 
  • Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: Report From the National Cardiovascular Data Registry. 
  • Ventricular arrhythmia in the X-linked cardiomyopathy Barth syndrome. 
  • Ventricular arrhythmia inducibility predicts subsequent ICD activation in nonischemic cardiomyopathy patients: a DEFINITE substudy. 
  • Ventricular arrhythmia storms in postinfarction patients with implantable defibrillators for primary prevention indications: a MADIT-II substudy. 
  • Videos to reduce racial disparities in ICD therapy Via Innovative Designs (VIVID) trial: Rational, design and methodology. 
  • Virtual electrode effects in transvenous defibrillation-modulation by structure and interface: evidence from bidomain simulations and optical mapping. 
  • Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction. 
  • When Is It Safe Not to Reimplant an Implantable Cardioverter Defibrillator at the Time of Battery Depletion? 
  • When to implant an ICD following a myocardial infarction? 
  • Where patients with mild to moderate heart failure die: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Who are the MADIT patients? Multicenter Automatic Defibrillator Implantation Trial. 
  • Why do some patients have high defibrillation thresholds at defibrillator implantation? Answers from basic research. 
  • Why the Authors Use Cardiac Resynchronization Therapy with Defibrillators. 
  • Why the Authors Use Cardiac Resynchronization Therapy with Defibrillators. 
  • Y2K: effects on pacemaker and implantable defibrillator programmers. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Barker, Piers Christopher Andrew, Professor of Pediatrics, Pediatrics, Cardiology
  • Carboni, Michael Paul, Associate Professor of Pediatrics, Pediatrics, Cardiology
  • Middleton, John Paul, Associate Professor of Medicine, Medicine, Nephrology
  • Milano, Carmelo Alessio, Professor of Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • Neu, Wanda Krassowska, Professor Emeritus of Biomedical Engineering, Biomedical Engineering
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology
  • Patel, Uptal Dinesh, Adjunct Professor in the Department of Medicine, Medicine, Nephrology
  • Pitt, Geoffrey Stuart, Adjunct Professor in the Department of Medicine, Medicine, Cardiology
  • Swaminathan, Madhav, Professor of Anesthesiology, Anesthesiology, Cardiothoracic